Portfolio

AB CUBE SUPPORTS PHARMACEUTICAL PRODUCT SAFETY PROCESSES 

Established provider of multivigilance software in the pharmaceutical and cosmetics sectors.

With its SafetyEasy® Suite, AB CUBE offers its customers a simple and regulatory-compliant solution for reporting and processing vigilance processes. In addition to the recording of adverse reactions for combination products, AB CUBE covers a variety of other areas, such as biovigilance or cosmetovigilance. This combination offers manufacturers and marketing authorization holders the possibility to standardize their vigilance processes across different product areas and to ensure permanent compliance with the regulatory requirements of FDA, EMA and MHRA.

01

Databases installed

>400

02

Countries, in which AB CUBE supports its customers

>43

03

Users worlwide

>2000

BID’S CONTRIBUTION 

Together with BID Equity, the management plans to expand AB CUBE's business in Germany and abroad. In particular, a focus will be placed on extending the product portfolio and service offering. In addition, BID Equity supports the management of AB CUBE in the following areas:

  • Professionalisation of the sales model
  • Scaling of the existing sales model 
  • Professional financial and personnel management
  • Strengthening of the product development process
  • Professionalisation of inbound and CRM processes
  • Strengthening of project and service structures
  • Integration of corporate acquisitions


myneva

BID Equity Pharma news

13 Jan 2022

BID Equity Fund II, advised by BID Equity, has acquired AB CUBE, SAS based in Paris, an established provider of multivigilance software in the pharmaceutical and cosmetics sectors.

04 Feb 2021

BID Equity Fund II, a fund advised by BID Equity, acquires Fortress Medical Systems, the US-based vendor of Clindex®, an integrated CTMS and EDC system.

04 Feb 2021

BID Equity Fund II, a fund advised by BID Equity, acquires France-based Carenity, an anlytics platform supporting +500,000 patients and caregivers worldwide.

12 Sep 2019

BID Equity Fund II, a fund advised by BID Equity, acquires a majority stake in XClinical GmbH. XClinical is a leading international provider of software solutions for drug and medical device studies. The XClinical platform fully implements the CDISC standard, which significantly accelerates the analysis and submission of data to regulatory authorities.

Building groups is our passion. Let it infect you. Your company could also be the basis for the next great software group.

Let's talk